Comparisons of leptin, incretins and body composition in obese and lean patients with hypopituitarism and healthy individuals

Clinical Endocrinology

Volumn 58, Issue 1, 2003, Pages 65-71

  Mersebach, Henriette ^a   Svendsen, O L ^b   Holst, J J ^b   Astrup, A ^b   Feldt Rasmussen, U ^b  

^a Mental Health Services CPH   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE; GLUCOCORTICOID; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE 1; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE 2; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LEPTIN; POLYPEPTIDE; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HUMAN; HYPOPITUITARISM; LEAN BODY WEIGHT; MALE; MEASUREMENT; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTHROPOMETRY; BODY COMPOSITION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCAGON-LIKE PEPTIDES; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; LEPTIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; PEPTIDE FRAGMENTS; PEPTIDES; THINNESS;

EID: 0037232459     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01675.x     Document Type: Article

References (28)

1. Bjorntorp, P. & Rosmond, R. (1999) Hypothalamic origin of the metabolic syndrome X. Annals of the New York Academy of Sciences, 892, 297-307.
2. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J. & Bauer, T.L. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine, 334, 292-295.
3. Fisker, S., Vahl, N., Hansen, T.B., Jorgensen, J.O., Hagen, C., Orskov, H. & Christiansen, J.S. (1997) Serum leptin is increased in growth hormone-deficient adults: Relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year. Metabolism, 46, 812-817.
4. Flint, A., Raben, A., Astrup, A. & Holst, J.J. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation, 101, 515-520.
5. Florkowski, C.M., Collier, G.R., Zimmet, P.Z., Livesey, J.H., Espiner, E.A. & Donald, R.A. (1996) Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clinical Endocrinology, 45, 769-773.
6. Han, T.S., van Leer, E.M., Seidell, J.C. & Lean, M.E. (1995) Waist circumference action levels in the identification of cardiovascular risk factors: Prevalence study in a random sample. British Medical Journal, 311, 1401-1405.
7. Hartmann, B., Johnsen, A.H., Orskov, C., Adelhorst, K., Thim, L. & Holst, J.J. (2000) Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides, 21, 73-80.
8. Jorgensen, J.O., Pedersen, S.B., Borglum, J., Moller, N., Schmitz, O., Christiansen, J.S. & Richelsen, B. (1994) Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: A double-blind placebo-controlled study. Metabolism, 43, 872-877.
9. Jorgensen, J.O., Rosenfalck, A.M., Fisker, S., Nyholm, B., Fineman, M.S., Schmitz, O., Madsbad, S., Holst, J.J. & Christiansen, J.S. (2000) Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: A placebo-controlled study. European Journal of Endocrinology, 143, 593-599.
10. Juul, A., Bang, P., Hertel, N.T., Main, K., Dalgaard, P., Jorgensen, K., Muller, J., Hall, K. & Skakkebaek, N.E. (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism, 78, 744-752.
11. Krarup, T. & Groop, P.H. (1991) Physiology and pathophysiology of GIP: A review. Scandinavian Journal of Clinical Laboratory Investigation, 51, 571-579.
12. Kuzio, M., Dryburgh, J.R., Malloy, K.M. & Brown, J.C. (1974) Radio-immunoassay for gastric inhibitory polypeptide. Gastroenterology, 66, 357-364.
13. Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang, Y., Fei, H., Kim, S., Lallone, R. & Ranganathan, S. (1995) Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Medicine, 1, 1155-1161.
14. Mersebach, H., Sneppen, S.B. & Feldt-Rasmussen, U. (2001) Long-term growth hormone treatment improves body composition despite increasing BMI [Abstract 54]. The 7th International Pituitary Congress, Arizona.
15. Moller, N., Schmitz, O., Joorgensen, J.O., Astrup, J., Bak, J.F., Christensen, S.E., Alberti, K.G. & Weeke, J. (1992) Basal and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism, 74, 1012-1019.
16. Nielsen, J.H., Svensson, C., Galsgaard, E.D., Moldrup, A. & Billestrup, N. (1999) Beta cell proliferation and growth factors. Journal of Molecular Medicine, 77, 62-66.
17. Norrelund, H., Gravholt, C.H., Englaro, P., Blum, W.F., Rascher, W., Chistiansen, J.S. & Jorgensen, J.O. (1998) Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: Lack of impact of different modes of GH administration. European Journal of Endocrinology, 138, 644-652.
18. Orskov, C. & Holst, J.J. (1987) Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scandinavian Journal of Clinical Laboratory Investigation, 47, 165-174.
19. Orskov, C., Rabenhoj, L., Wettergren, A., Kofod, H. & Holst, J.J. (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes, 43, 535-539.
20. Rosen, T., Bosaeus, I., Tolli, J., Lindstedt, G. & Bengtsson, B.A. (1993) Increased body fat mass and decreased extracellular fluid Volume in adults with growth hormone deficiency. Clinical Endocrinology, 38, 63-71.
21. Rosmond, R. & Bjorntorp, P. (2000) The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. Journal of Internal Medicine, 247, 188-197.
22. Stewart, P.M., Toogood, A.A. & Tomlinson, J.W. (2001) Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Hormone Research, 56 (Suppl. 1), 1-6.
23. Tang-Christensen, M., Larsen, P.J., Thulesen, J., Nielsen, J.R. & Vrang, N. (2001) Glucagon-like peptide 2, a neurotransmitter with a newly discovered role in the regulation of food ingestion. Ugeskrift For Laeger, 163, 287-291.
24. Tedde, R., Pala, A., Melis, A., Sechi, G., Bilotta, F. & Realdi, G. (1995) Hyperinsulinemia and hypertension. Do intestinal hormones play a role? American Journal of Hypertension, 8, 99-103.
25. Wojdemann, M., Wettergren, A., Hartmann, B. & Holst, J.J. (1998) Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scandinavian Journal of Gastroenterology, 33, 828-832.
26. Yip, R.G. & Wolfe, M.M. (2000) GIP biology and fat metabolism. Life Science, 66, 91-103.
27. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. & Friedman, J.M. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425-432.
28. Zimmermann-Belsing, T., Dreyer, M., Holst, J.J. & Feldt-Rasmussen, U. (1998) The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clinical Endocrinology, 49, 589-595.